Open AccessBosutinib Reduces the Efficacy of Dasatinib in Triple-negative Breast Cancer Cell Lines
Author(s) -
Mike Tarpley,
Temesgen Abdissa,
Gary L. Johnson,
J. E. Scott
Publication year - 2014
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/y8sv-gs58
Subject(s) - dasatinib , bosutinib , triple negative breast cancer , medicine , oncology , cancer research , breast cancer , doxorubicin , cancer , chemotherapy , tyrosine kinase , receptor